HOME >> MEDICINE >> NEWS
Long-term outcomes for prostate cancer show IMRT Curative: 89 percent disease-free 8 years later

ent with neoadjuvant androgen deprivation.

Between April 1996 and January 2000, 561 patients with a median age of 68 (ranging from 46 to 86 years old) were treated with IMRT, an improved form of three-dimensional conformal radiation therapy (3D-CRT), also used in radiotherapy. IMRT uses enhanced planning treatment software that more precisely targets the prostate, allowing the beam of radiation to deliver a high dose (81 Gy) to the tumor target while sparing the adjacent bladder and rectum from exposure to the higher amounts of radiation. Perhaps because of this, the eight-year results show urinary continence was maintained for all patients, and only 1.6 percent of the five hundred sixty-one patients experienced rectal bleeding. The high-dose radiotherapy was curative for the majority of the patients in all three prognostic risk groups, with 89 percent of the favorable, 78 percent of the intermediate, and 67 percent of the unfavorable group alive after an average period of eight years. Of those men who were potent prior to IMRT, erectile dysfunction developed in 49 percent.

"This study confirms that we can improve patients' quality of life by reducing the side effects of radiotherapy while maintaining disease-free survival," said Dr. Zelefsky. "However, there is still room for improvement. We are incorporating image-guided approaches that may continue the excellent tumor control but further limit the area we are irradiating and reduce side-effects."


'"/>

Contact: Joanne Nicholas
nicholaj@mskcc.org
212-639-3137
Memorial Sloan-Kettering Cancer Center
27-Sep-2006


Page: 1 2

Related medicine news :

1. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
2. Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
3. Long-term aspirin use associated with reduced risk of dying in women
4. Long-term data on safety and effectiveness of antiobesity drugs needed
5. Long-term financial costs associated with prostate cancer treatment
6. Long-term effects of non-alcoholic fatty liver disease
7. Long-term abstinence may resolve many of the neurocognitive deficits associated with alcoholism
8. Long-term safety results released for breast cancer drugs
9. Long-term ibuprofen regimen after brain injury worsens cognition in animal study
10. Media availability: Long-term survival of heart attack patients with shock
11. Long-term estrogen therapy linked to breast cancer risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2016)... PRUSSIA, PA and LONDON, UK (PRWEB) , ... May 06, 2016 ... ... earn accolades for his success in changing the way the pharmaceutical industry conducts clinical ... list of the world’s most influential people in pharma, and he was honored as ...
(Date:5/6/2016)... ... May 06, 2016 , ... US Sports Camps has collaborated with State Rugby ... State University this summer. Employing world-class rugby figures, including former Team USA players and ... training on key fundamentals, match play, fitness and more. , “US Sports Camps is ...
(Date:5/6/2016)... ... May 06, 2016 , ... Innovations with Ed ... airing third quarter 2016, via Discovery Channel. Dates and show times TBA. , ... optimized drug discovery through innovative cellular analysis. In this segment, viewers will learn ...
(Date:5/6/2016)... ... ... Online HR/benefits platforms offer a range of benefits functions to employers of all ... “ The Rapid Emergence of Online Benefits Firms: Strategies for Health Plans and Brokers ... an accurate picture of online benefits today, and the possible risks and rewards. Featuring ...
(Date:5/6/2016)... ... ... Mark Black is a speaker, author, and life strategy coach who is spreading the ... help of his publisher Strategic Book Group and its subsidiary Publish on Demand Global ... a miracle: He needed a heart and double-lung transplant. From this came a life-changing transformation ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and ... Systemic Lupus Erythematosus Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Systemic Lupus Erythematosus Market and Competitive Landscape ... Systemic Lupus Erythematosus pipeline products, Systemic Lupus ...
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 ... BVXV) announced today that BiondVax,s CEO, Dr. Ron Babecoff ... in New York City . ... 10:30am at Pioneers 2016, a conference presented by Joseph ... Palace Hotel. The BiondVax presentation that Dr. Babecoff ...
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
Breaking Medicine Technology:
Cached News: